State Street’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.42M | Buy |
54,821
+4,100
| +8% | +$118K | ﹤0.01% | 3398 |
|
|
2025
Q4 | $1.38M | Buy |
50,721
+12,624
| +33% | +$221K | ﹤0.01% | 3450 |
|
|
2025
Q3 | $571K | Buy |
+38,097
| New | +$439K | ﹤0.01% | 3633 |
|
|
2024
Q3 | – | Sell |
-1,503
| Closed | -$20.2K | – | 4309 |
|
|
2024
Q2 | $20.2K | Sell |
1,503
-164
| -10% | -$2.65K | ﹤0.01% | 4276 |
|
|
2024
Q1 | $29.2K | Hold |
1,667
| – | – | ﹤0.01% | 4248 |
|
|
2023
Q4 | $34.2K | Hold |
1,667
| – | – | ﹤0.01% | 4264 |
|
|
2023
Q3 | $27.6K | Hold |
1,667
| – | – | ﹤0.01% | 4403 |
|
|
2023
Q2 | $43.3K | Hold |
1,667
| – | – | ﹤0.01% | 4453 |
|
|
2023
Q1 | $42.1K | Hold |
1,667
| – | – | ﹤0.01% | 4545 |
|
|
2022
Q4 | $41.7K | Hold |
1,667
| – | – | ﹤0.01% | 4597 |
|
|
2022
Q3 | $45K | Hold |
1,667
| – | – | ﹤0.01% | 4679 |
|
|
2022
Q2 | $54K | Sell |
1,667
-18,141
| -92% | -$576K | ﹤0.01% | 4709 |
|
|
2022
Q1 | $723K | Sell |
19,808
-2,646
| -12% | -$100K | ﹤0.01% | 3909 |
|
|
2021
Q4 | $1.2M | Buy |
22,454
+3,898
| +21% | +$262K | ﹤0.01% | 3771 |
|
|
2021
Q3 | $1.37M | Buy |
18,556
+11,293
| +155% | +$6.26M | ﹤0.01% | 3724 |
|
|
2021
Q2 | $6.11M | Buy |
+7,263
| New | +$6.54M | ﹤0.01% | 3144 |
|
|
2020
Q4 | – | Sell |
-166
| Closed | -$201K | – | 3895 |
|
|
2020
Q3 | $201K | Buy |
+166
| New | +$110K | ﹤0.01% | 3665 |
|
|
2020
Q2 | – | Sell |
-940
| Closed | -$430K | – | 3831 |
|
|
2020
Q1 | $430K | Sell |
940
-488
| -34% | -$191K | ﹤0.01% | 3474 |
|
|
2019
Q4 | $286K | Sell |
1,428
-81
| -5% | -$18.4K | ﹤0.01% | 3591 |
|
|
2019
Q3 | $375K | Buy |
1,509
+591
| +64% | +$897K | ﹤0.01% | 3542 |
|
|
2019
Q2 | $2.3M | Buy |
918
+88
| +11% | +$261K | ﹤0.01% | 3183 |
|
|
2019
Q1 | $3.38M | Buy |
830
+47
| +6% | +$182K | ﹤0.01% | 2937 |
|
|
2018
Q4 | $2.41M | Buy |
783
+88
| +13% | +$379K | ﹤0.01% | 3045 |
|
|
2018
Q3 | $4.06M | Buy |
695
+131
| +23% | +$499K | ﹤0.01% | 2960 |
|
|
2018
Q2 | $1.98M | Buy |
564
+77
| +16% | +$282K | ﹤0.01% | 3262 |
|
|
2018
Q1 | $2.17M | Buy |
487
+136
| +39% | +$630K | ﹤0.01% | 3137 |
|
|
2017
Q4 | $1.35M | Buy |
351
+112
| +47% | +$447K | ﹤0.01% | 3294 |
|
|
2017
Q3 | $1.12M | Sell |
239
-1
| -0.4% | -$4.46K | ﹤0.01% | 3359 |
|
|
2017
Q2 | $1.08M | Buy |
+240
| New | +$1.35M | ﹤0.01% | 3323 |
|
Other funds holding FBRX
FAM
O
AAA
MB
VCM
CCC
State Street's FBRX Position: Q1 2026 in Review
State Street increased its Forte Biosciences (FBRX) stake by 8.1% in Q1 2026, buying an estimated $118K and bringing the position to 54,821 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3398.
State Street first reported a position in FBRX in Q2 2017 and has held it in 29 quarters since. The position peaked at $6.11M in Q2 2021. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.
- State Street held 54,821 shares of Forte Biosciences worth $1.42M as of Q1 2026.
- State Street bought 4,100 Forte Biosciences shares in Q1 2026, an estimated $118K.
- Forte Biosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3398 holding.
- State Street first reported a position in Forte Biosciences in Q2 2017 and has held it in 29 quarters since.
- State Street's Forte Biosciences position peaked at $6.11M in Q2 2021.
- 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.